Currently lead Reunion Neuroscience as President and CEO and Board Member (2022 to present). Mr. Mayes’ primary focus is on the successful completion of the Company’s clinical trial called RECONNECT with its lead asset, RE104, a novel serotonergic psychedelic. The Phase 2 study in postpartum depression commenced in 2024 and is expected to be completed in 2025. Additional information about the study is available at https://ppdreconnectstudy.com. Mr. Mayes will also advance RE104 in other neuropsychiatric indications and accelerate Reunion’s preclinical RE200 research, which is focused on the discovery of selective and specific serotonergic psychedelics.

Prior to joining Reunion, Mr. Mayes served in multiple C-Suite leadership roles at early-stage biotech and pharmaceutical companies, where he was integral in raising nearly half a billion dollars in investment capital and overseeing the successful completion of multiple early-phase FDA trials. As President and CEO of Antios Therapeutics, a clinical-stage biopharmaceutical company, Mayes led a $100+ million Series B financing with top healthcare investors in 2021. Prior to Antios, and inspired by his son’s epilepsy diagnosis, Mr. Mayes founded Engage Therapeutics, where he successfully raised $40 million in a Series A financing round led by TPG. He served as the Engage Therapeutics President and CEO from 2017 until 2020 when the company was acquired by UCB Pharma for $270 million, following a positive, randomized Phase 2b clinical trial evaluating its lead product candidate, a REST (Rapid Epileptic Seizure Termination) treatment.

• 

  President & Chief Executive Officer in Reunion Neuroscience

  Biotech research pioneer treating mental health conditions through the development of novel psychedelic compounds.